Novartis doubles Boston expansion to $600M

Already beefing up operations in Cambridge, Massachusetts, Novartis now plans to double the size of that expansion to $600 million. The new office and lab complex will also get an extra 200 to 300 employees over the next five years, the Boston Globe reports. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.